Trials / Unknown
UnknownNCT06118619
A Multicenter Clinical Trial of Ingaron in Pulmonary Tuberculosis
A Multicenter Clinical Trial of Recombinant Human Interferon Gamma (Ingaron) in Pulmonary Tuberculosis
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 350 (estimated)
- Sponsor
- SPP Pharmaclon Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 78 Years
- Healthy volunteers
- —
Summary
The main purpose of testing: To confirm the effectiveness and safety of the drug Ingaron when used in patients hospitalized at the research center for various reasons.
Detailed description
Monitoring of a patient in a hospital is carried out daily by the attending physician during the entire period of the patient's stay at the research center. When prescribing the drug Ingaron, the researcher must follow the instructions for use of the drug. As part of 4 control observations to assess effectiveness and safety: * 1st on the 1st day of using the drug Ingaron and starting anti-tuberculosis therapy * 2nd on the 30th - 31st day of therapy * 3rd after 2 months of therapy * 4th (final) after 3 months of follow-up After each of the 3 visits, the research doctor saves the data necessary for further evaluation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Interferon-Gamma | received by microbiological synthesis; specific antiviral activity on cells is 2x10\*7 Units per mg of protein |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2023-12-31
- Completion
- 2024-03-01
- First posted
- 2023-11-07
- Last updated
- 2023-11-09
Locations
13 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT06118619. Inclusion in this directory is not an endorsement.